Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'
Tweet Send to a Friend
Barclays raised its price target on Puma Biotech (NASDAQ: PBYI) to $122.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
